DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers.
Grievink HW, Heuberger JAAC, Huang F, Chaudhary R, Birkhoff WAJ, Tonn GR, Mosesova S, Erickson R, Moerland M, Haddick PCG, Scearce-Levie K, Ho C, Groeneveld GJ, 2019 Aug 31
View publication
